Merrimack Pharmaceuticals, Inc. (MACK)

NASDAQ: MACK · IEX Real-Time Price · USD
14.68
-0.05 (-0.34%)
At close: Apr 12, 2024, 4:00 PM
14.69
+0.01 (0.07%)
After-hours: Apr 12, 2024, 6:54 PM EDT
-0.34%
Market Cap 213.33M
Revenue (ttm) n/a
Net Income (ttm) -1.18M
Shares Out 14.53M
EPS (ttm) -0.08
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 109,214
Open 14.72
Previous Close 14.73
Day's Range 14.68 - 14.73
52-Week Range 11.53 - 15.89
Beta 1.43
Analysts n/a
Price Target n/a
Earnings Date May 2, 2024

About MACK

Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company in the United States. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts. [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Mar 29, 2012
Country United States
Stock Exchange NASDAQ
Ticker Symbol MACK
Full Company Profile

Financial Performance

Financial Statements

News

Merrimack Receives $225 Million Milestone Payment from Ipsen

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced that it has received a $225 million payment which was due from Ipsen, S...

18 days ago - Business Wire

Merrimack Reports Full Year 2023 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Reports Full Year 2023 Financial Results.

5 weeks ago - Business Wire

Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) reported that Ipsen, SA (“Ipsen”) issued a press release today announcing the U.S. Food...

2 months ago - Business Wire

Merrimack Reports Third Quarter 2023 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Reports Third Quarter 2023 Financial Results.

5 months ago - Business Wire

Merrimack Reports Second Quarter 2023 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Reports Second Quarter 2023 Financial Results.

9 months ago - Business Wire

Merrimack College Teacher Survey Highlights Troubling K-12 Teacher Morale Issues

NORTH ANDOVER, Mass.--(BUSINESS WIRE)--A newly released study shines a spotlight on a pressing crisis facing American education: Only 46% of current public K-12 educators would be “fairly” or “very li...

11 months ago - Business Wire

Merrimack Reports First Quarter 2023 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced its first quarter 2023 financial results for the period ended March 3...

1 year ago - Business Wire

Merrimack Reports Full Year 2022 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced its full year 2022 financial results for the period ended December 31, ...

1 year ago - Business Wire

Merrimack Pharmaceuticals Extends Section 382 Net Operating Loss Rights Plan

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (the “Company” or “Merrimack”), announced today that its Board of Directors (the “Board”) has extended the Section 3...

1 year ago - Business Wire

Merrimack stock rockets 200% after positive trial data on Onivyde pancreatic cancer treatment

Shares of Merrimack Pharmaceuticals Inc. MACK, +224.14% skyrocketed 199.5% toward a 4 1/2-year high in morning trading Wednesday, after the France-based biopharmaceutical company Ipsen IPSEY, +1.39% I...

1 year ago - Market Watch

Merrimack Reports Third Quarter 2022 Financial Results

CAMBRIDGE, Mass.

1 year ago - Business Wire

Merrimack Reports Second Quarter 2022 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Reports Second Quarter 2022 Financial Results

1 year ago - Business Wire

Merrimack Provides Ipsen Report of Results From Phase III RESILIENT Trial Evaluating Onivyde® in Second-Line Monotherapy for Small Cell Lung Cancer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Provides Ipsen report of results from Phase III RESILIENT trial evaluating Onivyde® in second-line monotherapy for small cell lung cancer

1 year ago - Business Wire

Merrimack Reports First Quarter 2022 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced its first quarter 2022 financial results for the period ended March 3...

2 years ago - Business Wire

Merrimack Reports Full Year 2021 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Reports Full Year 2021 Financial Results

2 years ago - Business Wire

Merrimack Reports Third Quarter 2021 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals Reports Third Quarter 2021 Financial Results

2 years ago - Business Wire

Merrimack Reports Second Quarter 2021 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) (“Merrimack” or the “Company”) today announced its second quarter 2021 financial results for the period ended June 30, ...

2 years ago - Business Wire

Merrimack Reports Full Year 2020 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Reports Full Year 2020 Financial Results

3 years ago - Business Wire

Merrimack Reports Third Quarter 2020 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals Q3 2020 Earnings Release

3 years ago - Business Wire

Merrimack Reports Second Quarter 2020 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Reports Second Quarter 2020 Financial Results

4 years ago - Business Wire